Cohiba Announces New Riviera Line to Debut in May as Full Collection

April 14, 2023 By Matthew Tabacco

 

 

Cohiba will welcome its first full-time new collection since 2020 with Cohiba Riviera, a six-region blend that features the very best of Central American tobacco and is named after the lush San Andrés Tuxtla Valley that bore the cigar’s wrapper.

Cohiba Riviera marks the first time a Mexican San Andrés wrapper has been used in a Cohiba blend and is the first box-pressed offering from the brand.

Cohiba Brand Ambassador Sean Williams said, “Cohiba Riviera is a bold yet balanced blend of the most exceptional tobaccos from Nicaragua with exclusively-grown tobaccos from Honduras. Medium-to-full bodied and adorned with a delectable wrapper from Mexico, Riviera is an elegant selection offering notes of dark chocolate and coffee bean with a hint of leather and subtle cream on the finish.”

The three-cigar collection is handcrafted in Nicaragua at STG Estelí. The Mexican San Andrés wrapper crowns a Honduran-grown Connecticut binder and filler tobaccos that include proprietary Honduran Jamastran and Honduran La Entrada, as well as Nicaraguan Condega and Nicaraguan Estelí.

“The experience of Cohiba Riviera is rich and rewarding and befitting of Cohiba’s status as an ultra-premium cigar brand,” noted Williams.

Cohiba Riviera will ship to retailers in May.

  • Cohiba Riviera Robusto (5″ x 52); SRP per cigar $19.99; 20 cigars per box

  • Cohiba Riviera Toro (6.5″ x 52); SRP per cigar $21.99; 20 cigars per box

  • Cohiba Riviera Perfecto (6″ x 60); SRP per cigar $23.99; 10 cigars per box

Related Posts

Perdomo Hires Michael Giannini

January 24, 2025 By Matthew Tabacco
Today, Perdomo Cigars announced that Michael Giannini, a longtime executive and figure of the cigar industry, has joined their Sales & Marketing team. Read more
FDA Updates

Cigar Industry Scores Second Win Against FDA in Regulation Case

January 24, 2025 By Matthew Tabacco
Today, the United States Court of Appeals for the District of Columbia issued its decision in CAA et al. v. FDA. Read more